Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03540420 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer

Study acronym: ACHILES
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv19
  2. Primary completion date changed from estimate of Apr 2024 to Apr 1, 2024
    • Study completion date: Apr 2027 to Apr 1, 2027
    v18
  3. Primary completion date: Dec 2023 to Apr 2024
    • Study completion date: Dec 2026 to Apr 2027
    v17
  4. Re-verified, no change to tracked fieldsv16
  5. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 41 of 41 sites
    v15
Show 13 earlier versionsHide 13 earlier versions
  1. Re-verified, no change to tracked fieldsv14
  2. Study sites: 25 to 41
    • Collaborators: 36 to 44
    v13
  3. Study sites: 21 to 25
    • Collaborators: 35 to 36
    v12
  4. Collaborators: 34 to 35v11
  5. Study sites: 16 to 21
    • Collaborators: 33 to 34
    v10
  6. Study sites: 10 to 16v9
  7. Re-verified, no change to tracked fieldsv8
  8. Site details revised at 1 of 10 sitesv7
  9. Study sites: 5 to 10
    • Collaborators: 9 to 33
    v6
  10. Study sites: 4 to 5v5
  11. Study sites: 3 to 4v4
  12. Study sites: 1 to 3v3
  13. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2018 to Jul 31, 2018
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is needed. Immunotherapy represents the largest advance in cancer therapy in recent years and has demonstrated promising activity in SCLC. In this study we will investigate whether atezolizumab prolongs survival in LD SCLC patients who have undergone chemo-radiotherapy.
Trial Details
NCT Number NCT03540420
Lead Sponsor Norwegian University of Science and Technology
Collaborators: University Hospital of North Norway, Alesund Hospital, Vestre Viken Hospital Trust, University Hospital, Akershus, Helse Nord-Trøndelag HF, Helse Stavanger HF, Haukeland University Hospital, Sorlandet Hospital HF, Ullevaal University Hospital, Molde Hospital, Helse Fonna, Nordlandssykehuset HF, Volda Hospital, Kristiansund Hospital, Sahlgrenska University Hospital, Skane University Hospital, Karolinska University Hospital, Ôrebro University Hospital, Gävle Hospital, University Hospital, Linkoeping, Odense University Hospital, Aalborg University Hospital, Rigshospitalet, Denmark, National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos, Kantonsspital Winterthur KSW, University Hospital, Basel, Switzerland, Insel Gruppe AG, University Hospital Bern, Kantonsspital Graubünden, Freiburger Spital, Klinik Hirslanden, Zurich, Kantonsspital Olten, Spital STS AG, Ente Ospedaliero Cantonale, Bellinzona, Cantonal Hospital of St. Gallen, St. Olavs Hospital, Oslo University Hospital, Rijnstate Hospital, Isala, Zuyderland Medisch Centrum, The Netherlands Cancer Institute, St. Antonius Hospital, Amphia Hospital, Medisch Spectrum Twente, Erasmus Medical Center
Conditions
(from sponsor)		 Small-cell Lung Cancer
Related terms Small Cell Lung Carcinoma
Enrollment 212 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov